Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betamethasone + methotrexate
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral, Intraarticular
01
Overview
Methotrexate combined with betamethasone is a combination drug used primarily for inflammatory and autoimmune conditions such as psoriasis and rheumatoid arthritis. Methotrexate is an antineoplastic and immunosuppressant agent that inhibits dihydrofolate reductase, leading to reduced DNA synthesis in rapidly dividing cells, thereby reducing inflammation and immune activity. Betamethasone is a potent corticosteroid that acts as a glucocorticoid receptor agonist, reducing inflammation by suppressing the immune response and inhibiting pro-inflammatory cytokines. The combination has been shown to clear psoriatic lesions faster and prolong remission compared to methotrexate alone. It can be administered orally or via injection depending on the clinical context. This combination leverages the immunosuppressive effects of both drugs for enhanced efficacy in controlling disease activity.[1][3][6][8]
- Other names
- betamethasone + methotrexate
02
Targets
GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on betamethasone + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betamethasone + methotrexate.